Clinical Trial

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

Study acronym: B-Kind
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-10; most recent amendment 2026-05-20.
Status change: Recruiting → Active, Not Recruiting 2026-05-20
Status change: Not Yet Recruiting → Recruiting 2025-10-14
Trial Details
NCT Number NCT07168356
Lead Sponsor GlaxoSmithKline
Conditions Hepatitis B
Enrollment 32 participants
Start Date 2025-09-26
Primary Completion 2026-03-03 (estimated)
Study Completion 2026-08-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-22